Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis

Elevated ribosome biogenesis in oncogene‐driven cancers is commonly targeted by DNA‐damaging cytotoxic drugs. Our previous first‐in‐human trial of CX‐5461, a novel, less genotoxic agent that specifically inhibits ribosome biogenesis via suppression of RNA polymerase I (Pol I) transcription, revealed...

Descripción completa

Detalles Bibliográficos
Autores principales: Kusnadi, Eric P, Trigos, Anna S, Cullinane, Carleen, Goode, David L, Larsson, Ola, Devlin, Jennifer R, Chan, Keefe T, De Souza, David P, McConville, Malcolm J, McArthur, Grant A, Thomas, George, Sanij, Elaine, Poortinga, Gretchen, Hannan, Ross D, Hannan, Katherine M, Kang, Jian, Pearson, Richard B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604608/
https://www.ncbi.nlm.nih.gov/pubmed/32945574
http://dx.doi.org/10.15252/embj.2020105111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604608/
https://www.ncbi.nlm.nih.gov/pubmed/32945574
http://dx.doi.org/10.15252/embj.2020105111

Ejemplares similares